Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03213691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Recurrent Childhood Central Nervous System Neoplasm
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Malignant Solid Neoplasm
Recurrent Neuroblastoma
Refractory Malignant Solid Neoplasm
Refractory Neuroblastoma
Refractory Non-Hodgkin Lymphoma
Refractory Primary Central Nervous System Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selumetinib
DRUG: Selumetinib Sulfate

Sponsor

National Cancer Institute (NCI)